




REMARKS

Claims 36-46 are pending, and claims 47-63 have been withdrawn.

Claim 36 has been amended to those R³ variables for which the Examiner notes at page 4, paragraph 4 of the Action to be enabled. Such should obviate the Examiner's rejection under 35 U.S.C. § 112, first paragraph for defining R³ as "aryl" or "heteroaryl". In view of this amendment, Applicants submit that the rejection is rendered moot.

Claims 39-42 have been amended to remove reference to the moiety  in the claims.

The claims now define variables in the moiety  of claim 36 from which they depend. Such should obviate the Examiner's rejections of the claims 39-42 under 35 U.S.C. § 112, second paragraph for

there being a lack of antecedent basis for the moiety  .. In view of this amendment, Applicants submit that the rejections are rendered moot.


Applicants submit that once compounds of the present invention are found to be allowable, then subject matter capable of rejoinder should be rejoined pursuant to the case law of *In re Ochai*.

Applicants request the reconsideration and withdrawal of the rejections in view of Applicants' amendments and response. Early action toward that end is appreciated.

The Commissioner is hereby authorized to charge any fee required hereunder and any additional fees that may be needed to Deposit Account No. **18-1982**.

Respectfully submitted,

Date: October 3, 2006


Raymond S. Parker, III, Ph.D., Reg. No. 34,893

sanofi-aventis U.S. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-5674
Telefax (908) 231-2626

Docket No. USA3676 US CNT